Advantages and limitations of the concept of antidepressant therapy

European Neuropsychopharmacology

Volumn 7, Issue SUPPL. 3, 1997, Pages

  Freeman, H L ^a  

^a 21 Montagu Square ^*  (United Kingdom)

Author keywords

Antidepressants; Co morbidity; Dysthmia; Elderly; Prophylaxis; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AFFECTIVE NEUROSIS; ANXIETY; CHRONIC PAIN; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSTHYMIA; ECONOMIC ASPECT; ELECTROCONVULSIVE THERAPY; EPILEPSY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEROTONINERGIC TRANSMISSION; SUICIDE;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DYSTHYMIC DISORDER; HUMANS;

EID: 0030663872     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00063-1     Document Type: Conference Paper

References (45)

1. A.H.C.P.R., 1993. Depression in Primary Care. Rockville, Maryland: US Department of Health and Human Services.
2. Akiskal H.S. Dysthymia: clinical and external validity. Acta Psychiatrica Scandinavia. 89(Suppl 383):1994;19-23.
3. Anderson I.M., Tomenson B.M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br. Med. J. 310:1995;1433-1438.
4. Blier P., De Montighy C., Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J. Clin. Psychiatry. 51(Suppl.):1990;14-20.
5. Buxton M. Economic appraisal and prescribing choices. Presc. J. 33:1993;133-137.
6. Coppen A. Long-term management of mood disorders: a therapeutic time bomb. Neuropsychopharmacology. 10:1994;355-364.
7. Cusack et al., 1994. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 114, 559-565.
8. Davis J.M. A comparative evaluation of the SSRIs, venlafaxine, and nefazodone. Directions in Psychiatry. 15(14):1995;1-8.
9. Donovan S., Freeman H.L. Deaths from antidepressants: a reconsideration. J. Drug Dev. 3:1990;120-127.
10. Duncan D., Taylor D. Which is the safest antidepressant to use in epilepsy? Psychiatr. Bull. 19:1995;355-357.
11. Dubovsky S.L., Thomas M. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. J. Psychosom. Res. 39:1995;429-444.
12. Fava, G.A., 1992. Depression in medical settings. In: Paykel, E.S. (Ed.), Handbook of Affective Disorders. Churchill Livingstone, London.
13. Freeling P., Rao B.M., Paykel E.S.et al. Unrecognised depression in general practice. Br. Med. J. 290:1985;1180-1183.
14. Freeman H.L. Moclobemide. Lancet. 342:1993;1528-1532.
15. Freeman H.L., O'Hanlon J.F. Acute and subacute effects of antidepressants on performance. J. Drug Dev. Clin. Practice. 7:1995;7-20.
16. Garvey M.J., Hollon S.D., DeRubeis R.J. Do depressed patients with higher pretreatment stress levels respond better to cognitive therapy than imipramine? J. Affect. Disord. 32:1994;45-50.
17. Goodwin, F.K., 1992. In: Goodwin, F.K., Jamison, K.R. (Eds.), Manic-Depressive Illness. Oxford University Press, New York.
18. Green, R.A., Nutt, D.J., 1987. In: Iversen, L.L., Iversen, S.D., Snyder, S.M. (Eds.), Handbook of Psychopharmacology, Plenum Press, New York.
19. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Bendt E.R. The economic burden of depression in 1990. J. Clin. Psychiatry. 54:1993;405-418.
20. Hindmarch I., Kerr J. Behavioural toxicity of antidepressants with particular reference to moclobermide. Psychopharmacology. 106:1992;549-555.
21. Holm J., Penzien D.B., Holroyd K.A., Brown T.A. Headache and depression confounding effects of transdiagnostic symptoms. Headache. 34:1994;418-423.
22. Isacsson G., Holmgren P., Wasserman D., Bergman U. Use of antidepressants among people committing suicide in Sweden. Br. Med. J. 308:1994;506-509.
23. Keller M.B., Lavori P.W., Endicott J.et al. Time-to-recovery chronicity in levels of psychopathology in major depression: a five year perspective follow-up of 431 subjects. Arch. Gen. Psychiatry. 49:1992;809-816.
24. Leonard, B.E., 1992. Effect of antidepressants on neurotransmission: a common mechanism of action? In: Osborne, N.N. (Ed.), Current Aspects of the Neurosciences, Vol 4. Macmillan, London.
25. Lock T. Advances in the practice of electroconvulsive therapy. Adv. Psychiatr. Treatment. 1:1994;47-56.
26. Lock T., McCullogh J. Local cerebral glucose utilization after chronic electroconvulsive therapy. J. Psychopharmacol. 5:1991;111-119.
27. McGuire A., Hughes D. The economic evaluation of depression. Postgrad. Med. J. 70(suppl. 2):1994;514-522.
28. Montgomery S.A., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int. Clin. Psychopharmacol. 9(Suppl. 4):1995;33-34.
29. Murphy, E., MacDonald, A., 1992. Affective disorders in old age. In: Paykel, E.S. (Ed.), Handbook of Affective Disorders. Churchill Livingstone, London.
30. Myers J.K., Weissman M.M., Tischler G.L.et al. Six month prevalence of psychiatric disorders in three communities. Arch. Gen. Psychiatry. 41:1964;959-967.
31. O'Hanlon J.F., Freeman H.L. Categorising the behavioural toxicity. Br. J. Psychiatry. 166:1995;421-423.
32. Ollat H. Le système dopaminergique mésolimbique: une voie finale commune pour les antidépressants. Psychologique Médicine. 20Q:1988;5-9.
33. Paykel E.S.et al. Recognition and management of depression in general practice: consensus statement. Br. Med. J. 305:1992;1198-1202.
34. Post R.M. Malignant transformation of affective illness: prevention and treatment. Directions in Psychiatry. 13(9):1993;1-8.
35. Post R.M., Leverich G.S., Ketter T.A.et al. The empirical and theoretical rationales for lifetime prophylaxis in bipolar affective illness. Neuropsychopharmacology. 10(Suppl. 3):1994;5160.
36. Regier D.A., Farmer M.E., Rae D.S.et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. J. Am. Med. Assoc. 264:1990;2511-2518.
37. Schildkraut J.J. Catecholamine hypothesis of affective disorder. Am. J. Psychiatry. 122:1965;509-522.
38. Siever, L.J., Coccaro, E.F., Benjamin, E., Rubenstein, K., Davis, K.L., 1986. Adrenergic and serotonergic receptor responsiveness in depression. In: Porter, R., Bock, G., Clark, S. (Eds.), Antidepressants and Receptor Function. Ciba Foundation, London.
39. Sims A.C.P. The mortality associated with depression. Int. Clin. Psychopharmacol. 3:1988;1-11.
40. Sitsen J.M.A., Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Drug Invest. 8:1994;339-344.
41. Stahl S.M. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol. Bull. 30:1994;39-43.
42. Stahl S.M., Frakes C.C. Nefazodone and the serotonin receptor modulators. Int. Rev. Psychiatry. 7:1955;29-39.
43. Task force of the CINP, 1993. Impact of neuropharmacology in the 1990s - strategies for the therapy of depressive illness. Eur. Neuropsychopharmacol. 3, 153-156.
44. Vassilas C., Morgan H.B. General practitioners' contact with victims of suicide. Br. Med. J. 307:1993;300-301.
45. WPA Dysthymia Working Group, 1995. Dysthymia in clinical practice. British Journal of Psychiatry 166, 174-183.